Pepinemab

SUSPENDED · PHASE1 · HER2-positive Breast Cancer

Wait for the DLT period with our current patient and will not be enrolling any more.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.